The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.
The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.
复制标题
DOI：
10.1111/1755-5922.12269
复制
发表时间：
2017-08
影响因子：
3.1
通讯作者：
Yazdani SK
中科院分区：
文献类型：
--
作者：
Atigh MK;Turner E;Christians U;Yazdani SK
非支架药物输送平台最近已成为外周动脉疾病的替代治疗方法。灌注导管有可能直接将抗增殖剂输送到动脉中层，以防止再狭窄。因此，本研究的目的是确定灌注导管输送紫杉醇（一种经证实的抗增殖剂）对抗再狭窄的有效性。一个台式模型被用来确定一种新的闭塞灌注导管的不同参数，以最大限度地使用药代动力学评价和荧光显微镜紫杉醇输送。测试的参数包括紫杉醇的浓度、递送压力、递送持续时间和赋形剂的使用。此外，用灌注导管处理双侧兔髂动脉，并在1小时、1天和3天进行药代动力学评价。实验室试验证明紫杉醇在经治疗动脉内均匀和周向渗透。离体试验的结果确定了具有和不具有相似负载条件的赋形剂的两个组（具有赋形剂：15.4±8.6 ng/mg与不具有赋形剂：8.9±6.9 ng/mg，p = 0.77）。这两组的体内药代动力学分析表明，使用造影剂可增加动脉紫杉醇水平，并维持初始紫杉醇剂量长达3天（含辅料：1小时：107±62 ng vs. 3天：40±23 ng，p = 0.824;无辅料：1小时：247±120 ng vs. 3天：2.92±2.9 ng，p=0.009）。这些结果证明了通过灌注导管将紫杉醇直接递送到动脉的中层的可行性。
Non-stent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver anti-proliferative agents to the medial arterial layer to prevent restenosis. The purpose of this study was to therefore determine the effectiveness of a perfusion catheter to deliver paclitaxel, a proven anti-proliferative agent, to combat restenosis. A bench-top model was utilized to determine the varying parameters of a novel occlusion perfusion catheter to maximize paclitaxel delivery using pharmacokinetic evaluation and fluorescent microscopy. Parameters tested included concentration of paclitaxel, delivery pressure, duration of delivery, and the use of an excipient. In addition, bilateral rabbit iliac arteries were treated with the perfusion catheter and pharmacokinetic evaluation performed at 1 hour, 1 day and 3 days. Bench-top testing demonstrated uniform and circumferential penetration of paclitaxel within the treated arteries. The results of the ex vivo test identified two groups with and without an excipient with similar loading conditions (with excipient: 15.4±8.6 ng/mg vs. without excipient: 8.9±6.9 ng/mg, p = 0.77). The in vivo pharmacokinetic analysis of these two groups demonstrated the use of contrast agent increased arterial paclitaxel levels and maintained initial paclitaxel dosing up to 3 days (With excipient: 1 hr: 107±62 ng vs. 3 days: 40±23 ng, p = 0.824; No excipient: 1 hr: 247±120 ng vs. 3 days: 2.92±2.9 ng, p=0.009). These results demonstrate the feasibility to deliver paclitaxel directly to the medial layer of an artery via a perfusion catheter.
登录
查看更多内容
影响因子：
39.3
作者：
Paneni F;Beckman JA;Creager MA;Cosentino F
通讯作者：
Cosentino F
影响因子：
11.3
作者：
Buszman, Piotr P.;Tellez, Armando;Granada, Juan F.
通讯作者：
Granada, Juan F.
影响因子：
11.3
作者：
Gongora, Carlos A.;Shibuya, Masahiko;Granada, Juan F.
通讯作者：
Granada, Juan F.
影响因子：
4.3
作者：
Kudo, T;Chandra, FA;Ahn, SS
通讯作者：
Ahn, SS
DOI：
10.1016/s0735-1097(03)01056-8
发表时间：
2003-10-15
影响因子：
24
作者：
Scheller, B;Speck, U;Nickenig, G
通讯作者：
Nickenig, G